Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants - sprookjes - yvandenbroek - TriplyDB

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

http://www.wikidata.org/entity/Q28303270

about

Advances and challenges in malaria vaccine development Immune mechanisms in malaria: new insights in vaccine development Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection Malaria vaccine: a future hope to curtail the global malaria burden Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies Immunogenicity of self-associated aggregates and chemically cross-linked conjugates of the 42 kDa Plasmodium falciparum merozoite surface protein-1 Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites The role of age and exposure to Plasmodium falciparum in the rate of acquisition of naturally acquired immunity: a randomized controlled trial Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial Sustainable development of a GCP-compliant clinical trials platform in Africa: the malaria clinical trials alliance perspective.Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children.A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.Malaria vaccines: where next?A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites.Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.Design and synthesis of potent Quillaja saponin vaccine adjuvants Watch out for malaria: still a leading cause of child death worldwide.MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation.A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray WHO policy development processes for a new vaccine: case study of malaria vaccines.Engaging diverse communities participating in clinical trials: case examples from across Africa.The RTS,S vaccine candidate for malaria.A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51 The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection.Malaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans?Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.Protection of Malian children from clinical malaria is associated with recognition of multiple antigens.RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites.

P2860

Q21032463-C3C187E5-0052-41E4-ABF3-969150A12D13 Q21032484-1B7B254A-EF2A-4A90-AA85-B73453F6AB92 Q24628167-A2E6ACD7-F1FD-4275-AF8A-3C6A7CB5F84D Q26996425-7C9D725A-F4FF-48CF-A470-BCD36E66092D Q28475084-39000019-1568-404F-BD28-F8EBD48D4F88 Q28484081-2D0EF484-618F-4C42-A2ED-F5AFEC5C9B03 Q28541281-553F5AA4-5AF4-4768-92FD-72A5DF256B0E Q28731458-0876F8C4-6B16-4019-8AC4-02FC00A6E4A0 Q28732752-471B598C-67D5-4FE4-8DFC-009432CEC08B Q28740701-C68A2554-890F-4B7E-88B9-79322002E164 Q28741059-47AC4039-7552-4690-A84A-AA82FB6D4B03 Q28744573-E741BA8D-EF02-44D3-9194-B3B234286287 Q28748331-7AC43C80-0A24-454F-B435-4CC8ABF556CD Q28748565-91EF180E-8499-4B9E-8376-0E382B5E15D5 Q30396940-316F7D7F-22AC-4B4B-B7F3-E92FFA3FC970 Q30596414-05BE7A0C-7F78-49A5-8128-4E0D101F45A2 Q30662529-9B494270-74E6-4CA0-93A4-FB0DE7A3D6C2 Q30895708-C4CCA77F-BD96-45C7-9DEF-082B153FFA01 Q33430011-E67D4CA1-7303-4CB0-ADC4-78911C8255AF Q33485233-46F29A57-9929-4609-A07C-D84829C27498 Q33489512-7E2BE834-B304-4D1D-AA91-258B6FA6851B Q33508797-C9D2265E-9E88-4C35-BBDD-311A6485249F Q33513966-AA1468D6-4DF0-442B-B465-4E79B471F595 Q33515022-0DB595F0-AC00-422B-A185-70915A4F4F7F Q33587443-0AD98FDA-9DD6-465D-BF9C-9C9C4CE62EE3 Q33645835-F3D9AC99-2E0E-4770-8797-0BD9E3DC4AC5 Q33688526-7C3D8652-7761-4260-8392-1C9C194F93A3 Q33726426-17A6619B-4613-4002-8244-D44C53AC2F4E Q33859633-A0BD5A59-4DDB-4C6F-841D-C9DE194A9421 Q34008911-2487143E-3DFD-4046-96B6-172D595CB42E Q34010897-AA359162-ADCF-4F52-98B9-953BC83C4D0C Q34186762-08B848BC-5240-4D55-8BD6-5D3876D826FA Q34487139-B04A0972-5D43-4E49-B0AD-AEE338B6F637 Q34541330-3D5836A0-D982-4CD2-93D6-0D0EDEB64A83 Q34546201-24A0C50A-6CDD-4A1C-B1F3-A4B4E981F56B Q34684347-6409663A-1F73-4A09-B6F4-A5CAC6029340 Q34983659-2FD2D6CE-6AA7-4CBB-87CE-322822E1CA71 Q35048336-6A55F6A1-05A2-44EE-8F73-E20E12BFAD22 Q35094826-199B0320-718E-437E-82DB-4F9FDB06E99C Q35148353-A339E6DC-C877-429F-B680-6064FA19CB1B

P2860

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

http://www.wikidata.org/entity/Q28303270

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@ast

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@en

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@nl

type

label

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@ast

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@en

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@nl

prefLabel

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@ast

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@en

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@nl

P1433

Q28303270-69951A3B-0CA2-4526-AC28-086B19B6C8E6

P1476

Q28303270-844AA08F-C4CD-4892-A5CE-D37A09B2EECB

P2093

Q28303270-00591E1B-82D3-4316-B187-36E0B27EB48A

Q28303270-25F2A554-B395-4301-A77C-944114F8A948

Q28303270-2F241ABB-FD25-466E-A22B-5E9C96C8AF5B

Q28303270-33AB1A96-C697-4470-A24D-D534CD66CD31

Q28303270-43773382-3FE0-4DDC-BDC1-C7A2E21BDAE1

Q28303270-50527D79-B386-4F64-B903-F8499D6477E8

Q28303270-5535ECAC-FDA4-4DFE-91FE-8D6692326EBB

Q28303270-643CDECB-E231-4486-86B2-7E5A40D8AF19

Q28303270-76D9CF53-E3D2-4664-9119-E7FB340E13B4

Q28303270-908496DF-5828-4EEB-BCAB-235A72129F46

P304

Q28303270-6B2C69BD-C621-4AD6-A341-4CE3A19A6D78

P31

Q28303270-CC3CAB7F-2183-4A2C-9B1D-FA3DCAA8C3CD

P3181

Q28303270-119F26DB-952E-4D00-B5AA-E5F43294071C

P356

Q28303270-881B589B-4E51-4063-9B1B-0C4F1D139E04

P407

Q28303270-B33FDC34-43AF-4A61-88BF-5599A9E0CE5E

P433

Q28303270-F33EF016-DB5C-4B19-8CF0-1938EE6FE387

P478

Q28303270-8A09AEF1-2078-4F92-A4FE-9CBFB179A0EF

P50

Q28303270-6A78B3EE-E192-4944-AB6A-9EF32942E3CB

Q28303270-AE3FA5EA-C83B-47C5-A2E6-E5C78DF3BCB6

Q28303270-B8B856B2-4D4D-4B11-B18D-EAD4938FB82D

Q28303270-B9455006-9E5A-4766-8C7B-9E2089D66ABD

Q28303270-C3640013-AE73-449B-B611-CA97EA9C061B

P577

Q28303270-429CB54B-AA72-4A6C-96AE-317D90CCF978

P698

Q28303270-F32EB43A-AE0A-4EDD-9894-C5D25033DE6B

P921

Q28303270-2F2F76C7-C62F-4DE1-AC89-FF647C4EE3B6

P3181

P356

P1433

The New England Journal of Medicine

P1476

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

@en

P2093

Ajuza Jumanne

http://www.w3.org/2001/XMLSchema#string

Alwisa Urassa

http://www.w3.org/2001/XMLSchema#string

Amanda Leach

http://www.w3.org/2001/XMLSchema#string

Christopher Membi

http://www.w3.org/2001/XMLSchema#string

David M Schellenberg

http://www.w3.org/2001/XMLSchema#string

Francisca Machera

http://www.w3.org/2001/XMLSchema#string

Joe Cohen

http://www.w3.org/2001/XMLSchema#string

Marc Lievens

http://www.w3.org/2001/XMLSchema#string

Marie-Ange Demoitié

http://www.w3.org/2001/XMLSchema#string

Marie-Claude Dubois

http://www.w3.org/2001/XMLSchema#string

P304

2533-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2369294

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0807773

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

W Ripley Ballou

P577

2008-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19064623

http://www.w3.org/2001/XMLSchema#string

P921